US govt loses appeal in GSK trade secret suit

Trade secret suit allegedly cost the pharma company over $1bn | Chinese researcher who stole approximately 200 GSK documents avoids paying restitution | Economic warfare.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

GSK bets $2.1bn on Boston-based biopharma company

1 June 2022 GlaxoSmithKline has agreed to acquire Affinivax, a clinical-stage biopharmaceutical company based in Cambridge, Boston and focusing on developing vaccines.

article

Swiss scientist convicted for GSK trade secrets theft

3 May 2022 A scientist working in Switzerland has been convicted of conspiring with his sister and others to steal trade secrets from GlaxoSmithKline for the benefit of their respective biopharmaceutical ventures.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

US govt loses appeal in GSK trade secret suit

More on this story

Editor's picks

Editor's picks

More features